Research Update on the Pathophysiological Mechanisms of Heart Failure with Preserved Ejection Fraction

Curr Mol Med. 2023;23(1):54-62. doi: 10.2174/1566524021666211129111202.

Abstract

Heart failure (HF) is a serious clinical syndrome, usually occurs at the advanced stage of various cardiovascular diseases, featured by high mortality and rehospitalization rate. According to left ventricular (LV) ejection fraction (LVEF), HF has been categorized as HF with reduced EF (HFrEF; LVEF<40%), HF with mid-range EF (HFmrEF; LVEF 40-49%), and HF with preserved EF (HFpEF; LVEF ≥50%). HFpEF accounts for about 50% of cases of heart failure and has become the dominant form of heart failure. The mortality of HFpEF is similar to that of HFrEF. There are no welldocumented treatment options that can reduce the morbidity and mortality of HFpEF now. Understanding the underlying pathological mechanisms is essential for the development of novel effective therapy options for HFpEF. In recent years, significant research progress has been achieved on the pathophysiological mechanism of HFpEF. This review aimed to update the research progress on the pathophysiological mechanism of HFpEF.

Keywords: Heart failure; cardiac reserve dysfunction; chronotropic incompetence; diastolic dysfunction; endothelial dysfunction; inflammation and oxidative stress; pulmonary hypertension.

Publication types

  • Review

MeSH terms

  • Heart Failure* / therapy
  • Humans
  • Stroke Volume